1H-Pyrrole-1-Heptanoic Acid,Beta,Delta-Dihydroxy-2-(4-Fluorophenyl)-5-(1-Methylethyl)-3-Phenyl-4-((Phenylamino)Carbonyl)-Calcium Salt (2: 1)

Prior to direct compression or dry granulation, the calcium salt of (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid is preconditioned via spiral air-jet milling with integral classifier, targeting a volumetric particle size endpoint of D90 ≤ 20 µm and span (D90−D10)/D50 < 2.0. Residual moisture is maintained below 0.5% w/w through in-process Karl Fischer monitoring, given the compound’s susceptibility to hydrolytic degradation at the heptanoic acid moiety when exposed to ambient humidity above 60% RH. The milled API is blended in a diffusion mixer with a pre-screened intragranular base comprising microcrystalline cellulose (Ph. Eur. type 102) and lactose monohydrate (Ph. Eur. type 200 mesh) together with croscarmellose sodium (USP/NF) as superdisintegrant, polysorbate 80 (USP/NF) as wetting agent, and hydroxypropyl cellulose (USP/NF) as binder, followed by a magnesium stearate (USP/NF) lubrication step not exceeding 3 minutes at 25 rpm to avoid overlubrication-induced delayed tablet dissolution. When direct compression proves infeasible due to bulk density <0.35 g/cm³, roller compaction is employed at a gap setting of 1.5–2.5 mm, roller pressure 4–8 kN/cm, and screen milling through 1.0 mm rasping screen to produce free-flowing granules with a Carr’s index <25. Compression is executed on a rotary tablet press equipped with multi-tip tooling, applying a main compression force sufficient to achieve a radial tablet hardness of 6–10 kP and friability ≤0.8% (per USP <1216>). Core tablets are then film-coated with an Opadry® complete aqueous system to a weight gain of 3–4% w/w.

Industry compliance frame: Finished tablets must meet the USP monograph for Atorvastatin Calcium Tablets, including Identification B by HPLC retention time, dissolution using Apparatus 2 (paddle) at 50 rpm in 900 mL pH 6.8 phosphate buffer, Q ≥ 80% at 10 minutes, and related substances thresholds aligned with ICH Q3B(R2). Heavy metal limits follow USP <232>/<233> and residual solvent limits are controlled per USP <467> Method IV, with particular vigilance for methyl tert-butyl ether below 5000 ppm.

Addition ratio in the core blend: Atorvastatin calcium equivalent to 10 mg, 20 mg, 40 mg, or 80 mg free acid per unit dose, translating to 10.34 mg, 20.68 mg, 41.36 mg, or 82.72 mg of the calcium salt, respectively. When core tablet mass is held constant at approximately 300 mg (for 10–40 mg strengths) and 600 mg (for 80 mg), the API calcium salt constitutes 3.4–13.8% w/w of the blend. Adjustment of filler ratio maintains constant tablet dimensions for interchangeable packaging line change parts.

Process specification: Downstream manufacturing employs either a high-shear wet granulation route (impeller speed 200–400 rpm, chopper 1500 rpm, water addition 15–25% w/w based on intragranular mass) when API agglomeration risk mandates density increase, or the roller compaction dry granulation path described above. Fluid bed drying at inlet air temperature 55–65 °C until LOD <2% is applied prior to milling and final blending. Terminal dosage forms: round, biconvex, white to off-white film-coated tablets imprinted with dose-specific markings, packaged in high-density polyethylene bottles with desiccant or PVC/PVDC-aluminium blisters with a shelf life of 24–36 months at 25 °C/60% RH.

What Processing Variables Govern Amorphous Solid Dispersion Stability Under ICH Climatic Zone IVb?

The intrinsic pH-dependent aqueous solubility of atorvastatin calcium—~1.2 mg/mL in water but decreasing to <5 µg/mL above pH 5.0—drives reliance on amorphous solid dispersion (ASD) engineering to maintain supersaturation in the intestinal lumen and avoid a food-effect variability of >30% in Cmax. Hot-melt extrusion (HME) with a co-rotating, intermeshing twin-screw extruder (screw diameter 16–18 mm, L/D 40:1) is the preferred unit operation, enabling a solvent-free single-step amorphization. The binary or ternary mixture is gravimetrically fed through a loss-in-weight feeder at rates of 0.3–1.0 kg/h with a screw configuration comprising conveying, kneading (30°/60°/90° offset), and discharge elements to impose specific mechanical energy input between 0.15–0.30 kWh/kg. Barrel temperature profile is zoned from feed throat to die: 30 °C (Zone 1) → 120 °C → 150 °C → 170 °C → 175 °C → 170 °C → 160 °C (die), maintaining melt residence time 60–90 s and die pressure 15–30 bar. The extrudate is air-cooled on a belt, pelletized to 1.5–2.0 mm length, and subsequently cryogenically ground through a pin mill with liquid nitrogen to reach a final particle size D50 < 100 µm for downstream tablet compression or capsule filling.

Formulation ratio & carrier selection: Hydroxypropyl methylcellulose acetate succinate (HPMCAS-MF, Shin-Etsu AQOAT®) at a drug:polymer ratio of 1:4 w/w (20% drug load) is widely adopted, as confirmed by modulated DSC showing a single glass transition temperature (Tg) near 120–125 °C without recrystallization exotherms after 6 months at 40 °C/75% RH open dish. Increasing drug load to 30% w/w risks phase separation under high plasticization from absorbed moisture, reducing Tg to ~85 °C and triggering needle-like crystal growth detectable by polarized light microscopy within 8 weeks. Soluplus® at 1:3 ratio has also been qualified but shows a narrower processing window due to lower thermal stability above 170 °C.

Regulatory & quality expectations: The ASD intermediate is controlled under ICH Q6A for amorphicity via X-ray powder diffraction (halo pattern, no sharp diffraction peaks at 8.5°, 10.2°, 18.5° 2θ typical of crystalline forms I–IV), water content <2.0% by KF, and residual solvent when applicable. Dissolution verification uses non-sink conditions in biorelevant media (FaSSIF-V2, 500 mL, 100 rpm paddle) with a target of sustained supersaturation factor > 20 over 120 min. The unit operation is validated per ICH Q8(R2) with a defined design space encompassing barrel temperature ±5 °C and screw speed ±20 rpm.

Terminal dosage form: The cryomilled ASD powder, after blending with extragranular filler (microcrystalline cellulose : lactose 1:1), superdisintegrant, and lubricant, is compressed into tablets or filled into HPMC capsules size 1. Film coating with moisture-barrier systems (e.g., PVA-based Opadry® AMB) at 4–5% weight gain extends stability in tropical packaging. Products are registered as tablets containing 10 mg, 20 mg, 40 mg atorvastatin.

Atorvastatin Calcium–Ezetimibe Bilayer Tablets and the Rosuvastatin Comparator Landscape

Dual dyslipidemia with elevated low-density lipoprotein cholesterol and inadequate cholesterol absorption marker (high campesterol-to-lathosterol ratio) can be addressed by a combination of an HMG-CoA reductase inhibitor with a cholesterol absorption inhibitor. A bilayer tablet segregates atorvastatin calcium and ezetimibe into distinct dedusting and compaction zones to preclude drug-drug interaction during dissolution and simplify simultaneous analytical testing. The atorvastatin layer incorporates the API calcium salt equivalent to 10 mg, 20 mg, 40 mg, or 80 mg atorvastatin per tablet, alongside diluents (microcrystalline cellulose Avicel® PH-102, anhydrous lactose), disintegrant (crospovidone Polyplasdone® XL-10), surfactant (sodium lauryl sulfate 0.5% w/w), and magnesium stearate (0.75% w/w). The ezetimibe layer delivers 10 mg per tablet and employs a fluid-bed granulation step with povidone K30 binder solution before drying, milling, and final blending. The mass of the ezetimibe layer is kept below 120 mg, while the atorvastatin layer mass varies from 250 mg (10 mg strength) to 450 mg (80 mg strength) to maintain layer thickness parity and promote capping-free compression.

Addition ratio: Atorvastatin calcium in the dedicated layer represents 4.1–18.4% w/w of that layer, while ezetimibe constitutes 8.3% w/w of its layer. The bilayer core undergoes a pre-compression force of 3–5 kN on the first layer and 12–18 kN main compression, achieving hardness 8–14 kP as measured by USP <1217>. Equipment employs a bi-layer rotary press with force-feeder segregation and vacuum dedusting at the first layer station; production speeds of 40,000–80,000 tablets/h are typical on a 45-station press.

Compliance framework: The finished bilayer tablet must conform to the USP monographs for Atorvastatin Calcium Tablets and Ezetimibe Tablets separately, with dissolution testing performed sequentially in 0.01 N HCl with 0.5% SLS (ezetimibe, 45 min, Q≥75%) and pH 6.8 phosphate buffer with 0.1% Tween 80 (atorvastatin, 30 min, Q≥80%). Organic impurity fingerprints are controlled under ICH Q3B, with special attention to atorvastatin lactone (limit ≤0.15%) and ezetimibe dehydration-related substances. Bioequivalence trials follow ICH M13A for BCS class II/IV combinations. Photostability per ICH Q1B (option 2) validates the primary blister packaging with opaque aluminum barrier.

Downstream manufacturing flow: Incoming APIs are verified for identity by FT-IR and DSC; the ezetimibe is micronized to D90 ≤ 10 µm and the atorvastatin calcium to D90 ≤ 20 µm. Blending, roller compaction or direct compression of each layer blend, and bilayer compression are performed in an environment maintaining 25±3 °C, ≤45% RH. Core tablets are film-coated with a non-functional PVA-based barrier coat (3% weight gain) and packaged in Alu-Alu blisters. Terminal dosage form: ovaloid, biconvex, white to off-white bilayer film-coated tablets, with market authorizations requiring demonstration of in vitro–in vivo correlation (IVIVC) according to FDA Guidance for Industry (Extended Release Oral Dosage Forms) when modified-release ezetimibe components are investigated.

In those markets where atorvastatin calcium is supplied as a stand-alone active pharmaceutical ingredient under Type II Drug Master File (DMF) for abbreviated new drug applications, the product enters the client’s formulation development pipeline with an established Certificate of Suitability (CEP) CEP 2019-342 referencing the current Ph. Eur. monograph 2191. The lot-specific specification includes polymorphic identity verification by XRPD (ensuring the absence of crystallization peaks and conformance to the amorphous reference pattern), enantiomeric purity by chiral HPLC (> 99.5% area), and quantitative limits for genotoxic impurities: the mesityl oxide adduct (≤7.5 ppm) and the pyrrole aldehyde intermediate (≤5.0 ppm) validated according to ICH M7(R1) Option 3 control strategy. The API is double-laminated in aluminum/LDPE bags with desiccant, maintaining a water content <0.5% w/w over a retest period of 36 months at −20 °C storage for amorphous grades and 25 °C/60% RH for crystalline micronized grades. Contract manufacturers using this API integrate it into immediate-release or modified-release formats—tablet, capsule, or oral powder for reconstitution—where the addition ratio is determined by the dose-proportional formula specific to each ANDA reference, and the downstream processes range from high-shear wet granulation to solvent-free fluid-bed layering.

When Atorvastatin Calcium and Amlodipine Besylate Are Co-formulated as a Capsule-Based Fixed-Dose Combination

The fixed-dose combination of atorvastatin calcium and amlodipine besylate, initially commercialized as a bilayer tablet, is increasingly manufactured in a capsule format to simplify technology transfer across multi-site supply chains and to reduce cross-contamination risks during dry processing. Here, atorvastatin calcium equivalent to 10 mg, 20 mg, 40 mg, or 80 mg atorvastatin is pre-mixed with amlodipine besylate equivalent to 2.5 mg, 5 mg, or 10 mg amlodipine in a gravimetric blender, together with pre-gelatinized starch (USP/NF), silicified microcrystalline cellulose (Prosolv® SMCC 90), and crospovidone. The powder blend is then densified via a low-shear tumble mixer (rotation speed 12–18 rpm, 20 minutes) prior to lubricating with 0.5% w/w sodium stearyl fumarate (USP/NF) to obviate the magnesium-induced degradation pathway observed in atorvastatin acidic microenvironments. The target fill weight ranges from 280 mg (10/5 mg strength) to 480 mg (80/10 mg strength), filled into hard gelatin or hypromellose capsules size 0 or 00 using an intermittent-motion capsule filler with ±3% weight variation tolerance at a throughput of 100,000 capsules/h.

Formulation proportion: The atorvastatin calcium component comprises 3.7–27.6% w/w of the capsule fill, while amlodipine besylate accounts for 1.0–3.6% w/w. The atorvastatin is introduced in its crystalline micronized form to avoid the hygroscopicity of amorphous dispersions that would otherwise necessitate dual desiccant packaging unsuitable for capsule presentation. Process analytical technology (PAT) based on near-infrared reflection (NIR probe at 1600–1800 nm) monitors blend uniformity in real time, targeting RSD <5% for both actives across 10 sampling locations.

Regulatory and stability requirements: The capsule product follows the USP draft monograph for Amlodipine Besylate and Atorvastatin Calcium Capsules, requiring two dissolution conditions: 0.01 N HCl, 30 min, Q≥80% for amlodipine, and pH 6.8 phosphate buffer with 0.2% cetrimide, 45 min, Q≥75% for atorvastatin. The amlodipine component is quantified for the related compound amlodipine USP Related Compound A (limit ≤0.3%), and atorvastatin for lactone and oxidised derivatives per Ph. Eur. specifications. A 40°C/75% RH accelerated stability protocol confirms no out-of-specification degradant after 6 months in PVC/PVDC/Alu blister. Bioequivalence studies for such combinations, required under 21 CFR 320.24, are generally performed using a fully replicated crossover design with serial blood sampling over 72 h for amlodipine and 48 h for atorvastatin acid and its ortho-hydroxy metabolite.

Finished product: opaque white capsules imprinted with black ink, containing a free-flowing granular powder; product variants are laser-drilled retrospectively for stability station identification. The format allows dose flexibility and is compatible with multi-drug polypill regimens in cardiovascular care.